Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: A retrospective review of Mayo Clinic experience

Mayo Clinic Proceedings

Volumn 80, Issue 1, 2005, Pages 41-47

  Wetter, David A ^a   Davis, Mark Denis P ^a   Yiannias, James A ^b   Gibson, Lawrence E ^a   Dahl, Mark V ^b   El Azhary, Rokea A ^a   Bruce, Alison J ^a   Lookingbill, Donald P ^c   Ahmed, Iftikhar ^a   Schroeter, Arnold L ^a   Pittelkow, Mark R ^a  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; CARIMUNE; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; DOXYCYCLINE; GLUCOCORTICOID; HYDROXYCHLOROQUINE SULFATE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; ISOTRETINOIN; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TETRACYCLINE; THALIDOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; CHRONIC URTICARIA; DERMATOMYOSITIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; FEMALE; FEVER; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; LEUKOCYTOCLASTIC VASCULITIS; LONG TERM CARE; MALE; MEDICAL RECORD; MIXED CONNECTIVE TISSUE DISEASE; MUCOUS MEMBRANE PEMPHIGOID; MYALGIA; NAUSEA; PEMPHIGOID; PEMPHIGUS VULGARIS; PLASMAPHERESIS; REVIEW; SCLEROMYXEDEMA; SKIN DISEASE; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

EID: 19944427764     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-6196(11)62956-x     Document Type: Review

References (21)

1. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol. 2002;47:358-363.
2. Ahmed AR, Sami N. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol. 2002;46:42-49.
3. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001;45:679-690.
4. Sami N, Bhol KC, Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol. 2002;102:59-67.
5. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology. 1999;106:2136-2143.
6. Prins C, Kerdel FA, Padilla RS, et al, TEN-IVIG Study Group. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139:26-32.
7. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol. 2003;139:39-43.
8. O'Donnell BF, Barr RM, Black AK, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol. 1998;138:101-106.
9. Gurmin V, Mediwake R, Fernando M, Whittaker S, Rustin MH, Beynon HL. Psoriasis: response to high-dose intravenous immunoglobulin in three patients. Br J Dermatol. 2002;147:554-557.
10. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol. 2000;27:2498-2503.
11. Gedalia A, Correa H, Kaiser M, Sorensen R. Case report: steroid sparing effect of intravenous gamma globulin in a child with necrotizing vasculitis. Am J Med Sci. 1995;309:226-228.
12. Khan IU, Bhol KC, Ahmed AR. Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy. J Am Acad Dermatol. 1999;40:485-488.
13. Lister RK, Jolles S, Whittaker S, et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol. 2000; 43:403-408.
14. Ulmer A, Kotter I, Pfaff A, Fierlbeck G. Efficacy of pulsed intravenous immunoglobulin therapy in mixed connective tissue disease. J Am Acad Dermatol. 2002;46:123-127.
15. Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol. 2002;138:1158-1162.
16. Sami N, Qureshi A, Ahmed AR. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. Eur J Dermatol. 2002;12:174-178.
17. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001;45:825-835.
18. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol. 2003;139:1051-1059.
19. Engineer L, Ahmed AR. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data. J Am Acad Dermatol. 2001;44:83-88.
20. Engineer L, Bhol KC, Ahmed AR. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol. 2000;43:1049-1057.
21. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology. 2002;59(suppl 6):S28-S32.